CBD Life Sciences Inc.
CBDL · OTC
3/31/2025 | 12/31/2024 | 9/30/2024 | 6/30/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.09 | 0.00 | 0.00 | 0.19 |
| FCF Yield | 3.37% | 0.00% | -25.01% | 0.00% |
| EV / EBITDA | -65.02 | -4.51 | -3.75 | -78.26 |
| Quality | ||||
| ROIC | -8.62% | -87.02% | -81.74% | -20.79% |
| Gross Margin | -78.27% | 39.62% | -71.62% | 40.16% |
| Cash Conversion Ratio | -1.22 | 0.87 | 0.05 | 1.41 |
| Growth | ||||
| Revenue 3-Year CAGR | -17.78% | -2.10% | 22.39% | 50.70% |
| Free Cash Flow Growth | 0.00% | 0.00% | 0.00% | 0.00% |
| Safety | ||||
| Net Debt / EBITDA | 6.67 | 0.02 | -0.03 | 0.36 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.72 | 0.22 | 1.77 | 2.28 |
| Cash Conversion Cycle | 1,066.07 | 409.03 | 50.90 | 314.68 |